It has been shown to reduce AGR2 expression in ovarian cancer, thereby suppressing cell proliferation, migration, and invasion when used alone, and inhibiting tumor growth and metastasis in vitro and in vivo when combined with paclitaxel [43]. Here, AGR2 is linked to neoplasm.